Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15Glioblastoma 14Neoplasms 12Brain Neoplasms 12Melanoma 11Pancreatic Neoplasms 10Head and Neck Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Prostatic Neoplasms 8Glioma 8Ovarian Neoplasms 7Neoplasm Metastasis 7Lymphoma 6Colonic Neoplasms 6Multiple Myeloma 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Leukemia, Myeloid, Acute 3

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Hemangioblastoma × Clear all
NCT01015300 2012-05-11

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Dartmouth-Hitchcock Medical Center

Phase EARLY_PHASE1 Terminated
1 enrolled

von Hippel-Lindau Disease, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡